Biodexa’s eRapa Shows Promise for FAP Treatment

Biodexa Pharmaceuticals Plc (BDRX) has released an update.

Biodexa Pharmaceuticals PLC announces that Emtora Biosciences will present results from the Phase 2 trial of eRapa for treating Familial Adenomatous Polyposis at the Digestive Disease Week 2024. Biodexa has secured an exclusive worldwide license to develop and commercialize eRapa, a novel oral tablet formulation of the mTOR inhibitor rapamycin, designed to improve bioavailability and reduce toxicity. eRapa, which has received Orphan Designation in the US, represents a potential first-of-its-kind treatment for FAP, a condition currently lacking approved therapeutic options.

For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.